Calliditas Therapeutics AB (publ) (STO: CALTX)
Sweden
· Delayed Price · Currency is SEK
208.00
+1.80 (0.87%)
Inactive · Last trade price
on Oct 10, 2024
STO: CALTX Income Statement
Financials in millions SEK. Fiscal year is January - December.
Millions SEK. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | 2018 - 2015 |
---|---|---|---|---|---|---|---|
Period Ending | Jun '24 Jun 30, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | Dec '19 Dec 31, 2019 | 2018 - 2015 |
Revenue | 1,601 | 1,207 | 802.88 | 229.35 | 0.87 | 184.83 | Upgrade
|
Revenue Growth (YoY) | 39.27% | 50.32% | 250.07% | 26141.08% | -99.53% | - | Upgrade
|
Cost of Revenue | 104.68 | 60.46 | 15.2 | - | - | - | Upgrade
|
Gross Profit | 1,497 | 1,146 | 787.68 | 229.35 | 0.87 | 184.83 | Upgrade
|
Selling, General & Admin | 1,314 | 1,061 | 774.66 | 390.23 | 141.72 | 62.88 | Upgrade
|
Research & Development | 557.91 | 502.22 | 414.75 | 357.49 | 241.37 | 149.83 | Upgrade
|
Other Operating Expenses | -4.83 | -25.95 | 13.08 | 4.47 | - | - | Upgrade
|
Operating Expenses | 1,867 | 1,537 | 1,202 | 752.19 | 383.1 | 212.71 | Upgrade
|
Operating Income | -370.67 | -390.58 | -414.81 | -522.84 | -382.22 | -27.88 | Upgrade
|
Interest Expense | -104.42 | -73.2 | -32.8 | -7.11 | -0.39 | -0.33 | Upgrade
|
Interest & Investment Income | 29.1 | 29.1 | 3.55 | 0.1 | 0.55 | 0.93 | Upgrade
|
Currency Exchange Gain (Loss) | 17.88 | 17.88 | 39.51 | 18.58 | -54.08 | -5.16 | Upgrade
|
Other Non Operating Income (Expenses) | -41.15 | -41.15 | -4.88 | -2.15 | - | - | Upgrade
|
EBT Excluding Unusual Items | -469.26 | -457.96 | -409.42 | -513.42 | -436.15 | -32.44 | Upgrade
|
Gain (Loss) on Sale of Assets | 0.94 | 0.94 | - | 0.04 | - | -0.06 | Upgrade
|
Pretax Income | -468.32 | -457.02 | -409.42 | -513.37 | -436.15 | -32.5 | Upgrade
|
Income Tax Expense | 12.04 | 9.17 | 2.85 | -3.84 | 0.36 | 0.08 | Upgrade
|
Earnings From Continuing Operations | -480.36 | -466.19 | -412.27 | -509.54 | -436.51 | -32.58 | Upgrade
|
Minority Interest in Earnings | - | - | - | 9.24 | 3.02 | - | Upgrade
|
Net Income | -480.36 | -466.19 | -412.27 | -500.29 | -433.49 | -32.58 | Upgrade
|
Net Income to Common | -480.36 | -466.19 | -412.27 | -500.29 | -433.49 | -32.58 | Upgrade
|
Shares Outstanding (Basic) | 54 | 54 | 53 | 51 | 45 | 37 | Upgrade
|
Shares Outstanding (Diluted) | 54 | 54 | 53 | 51 | 45 | 37 | Upgrade
|
Shares Change (YoY) | 0.40% | 1.22% | 4.32% | 13.27% | 21.47% | 42.36% | Upgrade
|
EPS (Basic) | -8.95 | -8.69 | -7.78 | -9.84 | -9.66 | -0.88 | Upgrade
|
EPS (Diluted) | -8.95 | -8.69 | -7.78 | -9.84 | -9.66 | -0.88 | Upgrade
|
Free Cash Flow | -257.72 | -447.44 | -313.87 | -468.18 | -309.18 | -71.13 | Upgrade
|
Free Cash Flow Per Share | -4.80 | -8.34 | -5.92 | -9.21 | -6.89 | -1.93 | Upgrade
|
Gross Margin | 93.46% | 94.99% | 98.11% | 100.00% | 100.00% | 100.00% | Upgrade
|
Operating Margin | -23.15% | -32.36% | -51.67% | -227.97% | -43732.38% | -15.08% | Upgrade
|
Profit Margin | -30.00% | -38.63% | -51.35% | -218.14% | -49598.86% | -17.63% | Upgrade
|
Free Cash Flow Margin | -16.09% | -37.07% | -39.09% | -204.13% | -35375.40% | -38.48% | Upgrade
|
EBITDA | -365.37 | -386.35 | -412.7 | -494.12 | -382.18 | -27.84 | Upgrade
|
EBITDA Margin | -22.82% | -32.01% | -51.40% | -215.45% | - | -15.06% | Upgrade
|
D&A For EBITDA | 5.3 | 4.23 | 2.11 | 28.72 | 0.04 | 0.04 | Upgrade
|
EBIT | -370.67 | -390.58 | -414.81 | -522.84 | -382.22 | -27.88 | Upgrade
|
EBIT Margin | -23.15% | -32.36% | -51.67% | -227.97% | - | -15.08% | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.